Enanta Pharmaceuticals Inc.
ENTA Nasdaq
SEC CIK 1177648
Follow Enanta Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$12.9M
−14.9% vs same quarter last year
Net income
−$23.7M
−26.8% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$13.7M
−111.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $63M | −$68.2M |
| FY25 | $65.3M | −$81.9M |
| FY24 | $67.6M | −$116M |
| FY23 | $79.2M | −$133.8M |
| FY22 | $86.2M | −$121.8M |
| FY21 | $97.1M | −$79M |
| FY20 | $122.5M | −$36.2M |
| FY19 | $205.2M | $46.4M |
| FY18 | $206.6M | $72M |
| FY17 | $102.8M | $17.7M |
| FY16 | $88.3M | $21.7M |
| FY15 | $160.9M | $79M |
| FY14 | $47.7M | $34.4M |
| FY13 | $32.1M | - |
| FY12 | $41.7M | $21.4M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY26 | −99% | −108.3% |
| FY25 | −130.7% | −125.4% |
| FY24 | −179.9% | −171.6% |
| FY23 | −173.2% | −169% |
| FY22 | −143.7% | −141.3% |
| FY21 | −112.9% | −81.4% |
| FY20 | −34% | −29.5% |
| FY19 | 17.9% | 22.6% |
| FY18 | 42.7% | 34.8% |
| FY17 | 23.9% | 17.2% |
| FY16 | 34.9% | 24.5% |
| FY15 | 77.2% | 49.1% |
| FY14 | 39.8% | 72.1% |
| FY13 | 28.2% | - |
| FY12 | 51% | 51.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | −$42.8M |
| FY25 | −$32.2M |
| FY24 | −$96.7M |
| FY23 | −$112.2M |
| FY22 | −$86.9M |
| FY21 | −$70.7M |
| FY20 | $5.6M |
| FY19 | $66M |
| FY18 | $26.2M |
| FY17 | $50.1M |
| FY16 | $31.1M |
| FY15 | $74.3M |
| FY14 | $19.2M |
| FY13 | $10M |
| FY12 | $22.4M |
- Enanta Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Enanta Pharmaceuticals | Healthcare median |
|---|---|---|
| FY26 | −108.3% | −11.1% |
| FY25 | −125.4% | −30.6% |
| FY24 | −171.6% | −47% |
| FY23 | −169% | −58% |
| FY22 | −141.3% | −80.4% |
| FY21 | −81.4% | −71.9% |
| FY20 | −29.5% | −62.2% |
| FY19 | 22.6% | −46.3% |
| FY18 | 34.8% | −49.6% |
| FY17 | 17.2% | −45.9% |
| FY16 | 24.5% | −36% |
| FY15 | 49.1% | −38.4% |
| FY14 | 72.1% | −35.5% |
| FY13 | - | −37.1% |
| FY12 | 51.3% | −29.1% |